1. REAL WORLD EFFICACY AND TOXICITY OF ANTI-PD1 TREATMENT IN ELDERLY PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC). (November 2019) Authors: Boutin, M.; De Angelis, F.; Éthier, V.; Speranza, G.; Berbiche, D. Journal: Journal of geriatric oncology Issue: Volume 10(2019)Supplement 1 Page Start: S42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S159: QUÉBEC CML RESEARCH GROUP ANALYSIS OF TREATMENT PATTERNS IN CHRONIC MYELOGENOUS LEUKEMIA: SWITCHING IS DRIVEN BY INTOLERANCE AND SIMILAR ACROSS TYROSINE KINASE INHIBITORS AND LINES OF TREATMENT. (23rd June 2022) Authors: Busque, L.; Harnois, M.; Szuber, N.; Delage, R.; Mollica, L.; Olney, H.; Laneuville, P.; Sirhan, S.; Cournoyer, G.; Chamakhi, I.; Lalancette, M.; Talbot, D.; Éthier, V.; Desjardins, P.; Assouline, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗